BookEric Murillo-Rodriguez, S. R. Pandi-Perumal, Jaime M. Monti, editors.
Summary: This volume highlights the recent advances in the understanding of the endocannabinoid system and the likely benefit from the therapeutic effects of cannabinoid treatment in a variety of health issues. Archeological evidence has shown that Cannabis has a long history of use for multiple purposes, including the treatment of medical conditions. The primary active constituent of the hemp plant Cannabis sativa, delta 9-tetrahydrocannabinol (Δ9-THC), causes euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concentration and impairment of memory, among other effects. Despite these undesirable effects, signaling is mostly inhibitory and suggests a putative role for cannabinoids as therapeutic agents by managing several diseases where inhibition of neurotransmitter release would be beneficial. The themes of this book have been edited and written by world-leaders in the field, The contents of the volume aims at readers from a range of academic and professional disciplines, such as biomedicine, several areas of biology, neurology, clinical medicine and pharmacy.
Contents:
Chapter 2: Neuromolecular Mechanisms of Cannabis Action
2.1 Introduction and Scope of this Chapter
2.1.1 Neuromolecular Targets of THC: The Cannabinoid Receptors
2.1.1.1 CB1 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology
2.1.1.2 CB2 Cannabinoid Receptor Characterisation: Protein, Distribution, Signalling and Pharmacology
2.1.2 Neuromolecular Targets of THC: Beyond the Cannabinoid Receptors
2.1.3 Neuromolecular Targets of CBD
2.1.4 Neuromolecular Targets of Other Cannabinoids
2.1.4.1 Delta9-Tetrahydrocannabidivarin 2.1.4.2 Cannabinol
2.1.4.3 Delta9-Tetrahydrocannabinolic Acid
2.1.4.4 Cannabidivarin
2.1.4.5 Cannabidiolic Acid
2.1.4.6 Cannabigerol
2.1.4.7 Cannabichromene
2.1.5 Concluding Remarks
References
Chapter 3: Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review
3.1 Introduction
3.2 Neuromolecular mechanisms of action of the main phytocannabinoids
3.2.1 THC
3.2.2 CBD
3.2.3 Delta-9-THCV
3.2.4 Delta-9-THCA
3.2.5 Delta-8-THC
3.2.6 CBDV
3.2.7 CBN
3.2.8 CBG
3.2.9 CBC
3.2.10 CBDA 3.3 Neurochemical and behavioral effects of THC and CBD: Human studies
3.3.1 THC
3.3.2 CBD
3.4 Approved indications of cannabis-based products, THC and CBD
3.4.1 Cannabis-based products
3.4.2 THC
3.4.2.1 Nausea and vomiting due to chemotherapy
3.4.2.2 Appetite and decreasing weight loss associated with HIV/AIDS
3.4.2.3 Multiple sclerosis symptoms (spasticity and chronic pain)
3.4.2.4 Chronic pain (neuropathic and cancer pain)
3.4.3 CBD
3.4.3.1 Antiepileptic
3.4.3.2 Therapeutic potentials of CBD with moderate/modest evidence from RCTs 3.5 Adverse effects of THC and CBD
3.5.1 Cannabis-based products and THC
3.5.2 CBD
3.6 Conclusions
References
Chapter 4: Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models
4.1 Introduction
4.1.1 Cannabinoid Classifications
4.2 Endocannabinoids
4.3 Phytocannabinoids
4.4 Synthetic Cannabinoids
4.5 Cannabinoids in Neuromodulation
4.5.1 Cannabinoids in Epilepsy
4.5.2 Cannabinoids in Alzheimerś Disease
4.5.3 Cannabinoids in Parkinsonś Disease
4.6 Cannabinoids in Cancer
4.7 Cannabinoids in Metabolic Disorders